Pharmaceutical agents that manipulate the activity of all three of these ligands are currently in development, however, targeting each has posed challenges, with questionable single-agent activity with adenosine and prostaglandin E2, and significant off-tumor effects with TGFβ. Here, TGFB1 is linked to neoplasm.